Asked by: Mohammad Yasin (Labour - Bedford)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether his Department recognises problem debt as a public health issue; and what support the NHS and social care services provide to people with problem debt.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
Research shows that there is a link between health and financial health with a large amount of people who experience mental health problems also struggling with their finances.
NHS Talking Therapies has recently collaborated with the Money and Pensions Service to promote the Money Guiders programme that helps equip mental health practitioners to have money conversations with their patients. In addition, each NHS Talking Therapies service has embedded employment advisors who provide a non-clinical support service to help patients using Talking Therapies to address work-related issues, offering practical support and solutions for any work barriers which can include unemployment and returning to work.
The Individual Placement and Support is a well‑evidenced, National Institute for Health and Care Excellence‑approved employment programme, funded by NHS England, that offers intensive, individually tailored support to get people into work, with ongoing support for the employer and employee to help ensure the person keeps their job.
Individuals may also be able to access the Breathing Space Scheme, which was set up to encourage more people in problem debt to access professional debt advice. A standard breathing space provides a 60-day period of protection by pausing creditor enforcement action and most interest, fees, and charges. Given the link between problem debt and mental health difficulties, the Mental Health Crisis Breathing Space was also established for individuals who are receiving mental health crisis treatment.
Where debt is the result of gambling addiction, individuals can access their local National Health Service gambling service via self- or professional referral.
Asked by: Mohammad Yasin (Labour - Bedford)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what pilots or trials are being planned to reduce drug-related deaths in areas with the highest rates of overdose.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
Local authorities are responsible for assessing local need for drug prevention, treatment, and recovery in their areas and for commissioning services to best meet local need. This includes work to reduce drug-related deaths.
The Department has recently launched the Drug and alcohol-related deaths dashboard, which provides information on the levels of drug and alcohol related mortality and harms, and the evidence-based interventions that local authorities and treatment providers can provide to have a positive impact on reducing deaths. Local authorities have access to this dashboard and can use it to assess need and plan interventions including in areas with higher rates of deaths. We are also improving surveillance of emerging harms and drug use patterns, with quarterly surveillance data now published to support local police and health responses to synthetic opioids.
In response to increasing drug related deaths, in 2024 the Department amended the Human Medicines Regulations 2012 to expand access to naloxone. The legislation enabled more services and professionals to supply this medication. The Department has recently launched a 10-week United Kingdom-wide public consultation on further legislative options to expand access to take-home and emergency use naloxone.
In response to the sharp rise in deaths involving cocaine, 800 deaths in 2022 to 1,195 deaths in 2024, the Department is investing an additional £200,000 in 2025/26 to develop and trial new brief interventions to target the rise in cocaine and alcohol-related cardiovascular deaths, particularly among men. The pilots will be run in acute hospital alcohol care teams with a view to making them available for use nationally across all healthcare settings in the next financial year.
Through the Government's Addiction Healthcare Goals Reducing Drug Deaths Innovation Challenge, twelve projects have received UK and Scottish government funding to develop and test innovative drug overdose detection, response, and rescue technologies and medicines with relevant populations. Future funding and support through the Addiction Healthcare Goals programme are being explored to further enable the advanced development and UK roll-out of novel drug and alcohol addiction technologies to improve healthcare and prevent harms and deaths.
Asked by: Mohammad Yasin (Labour - Bedford)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what plans his Department has to expand access to drug checking services, naloxone, and other overdose prevention measures.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
Every drug-related death is a tragedy, and the Government is taking a public health approach to prevent these deaths and reduce harms from drugs.
Expanding access to naloxone, a life-saving overdose medication, has never been more important. In addition to the changes made in 2024 to expand access, we recently launched a ten-week United Kingdom-wide public consultation on further legislative options to expand access to take-home and emergency use naloxone.
The Government facilitates Drug Checking Facilities provided that the possession and supply of controlled drugs are licensed by the Home Office, or exceptionally, relevant exemptions under the Misuse of Drugs Regulations 2001 may apply. Drug Checking Facilities must not condone drug use and should only be delivered where licensed and operated responsibly in line with Government policy to ensure that they discourage drug use and signpost potential users to treatment and support.
Asked by: Mohammad Yasin (Labour - Bedford)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether he plans to issue revised guidance on the placement of people with Gender Recognition Certificates who have undergone surgery on hospital wards.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
NHS England is currently reviewing its Delivering same-sex accommodation guidance and will ensure that it reflects the Supreme Court’s For Women Scotland Ltd v. The Scottish Ministers ruling, and is aligned with the Equality and Human Rights Commission’s statutory Code of Practice (the Code) when that becomes available.
Asked by: Mohammad Yasin (Labour - Bedford)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of trends in the level of corn allergies; whether he plans to include corn on the list of major allergens emphasised on food labels; and what steps he is taking to ensure that people with rare but clinically significant allergies can safely identify allergens in packaged foods and when eating out.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
There are a large number of potential food ingredients that may cause allergic reactions in sensitised individuals. The current 14 regulated allergens are recognised as the most common and potent allergens of public health concern across Europe. They must be clearly identified on prepacked foods and communicated effectively when eating out.
Available evidence, though limited, suggests corn allergy remains rare in the United Kingdom, with no indication of an increasing trend, and it is not part of the current list of regulated allergens.
The Food Standards Agency (FSA) ensures that labelling requirements enable consumers to make informed choices about all ingredients, including corn.
Food businesses must provide clear and accessible allergen information. For prepacked and prepacked for direct sale foods, this means naming the food and listing all ingredients so consumers can identify allergens before purchase. For non-prepacked foods, such as meals served in restaurants or cafés, the FSA’s Best Practice Guidance, published March 2025, recommends written information supported with a clear conversation with customers about their allergy requirements. Businesses should keep accurate ingredient records and inform consumers if they cannot confirm allergen content. Consumers should declare their allergies when ordering food to help businesses take appropriate steps and reduce risk.
At present, the FSA has no plans to amend the list of 14 allergens. It continues to monitor trends through research projects, including National Health Service data analysis and the Patterns and Prevalence of Adult Food Allergy study, and works with the British Society for Allergy and Clinical Immunology and other stakeholders to gather evidence on hidden and emerging allergens.
Asked by: Mohammad Yasin (Labour - Bedford)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to ensure that patients with multiple weight-related health conditions who fall below the current NHS eligibility threshold for tirzepatide, also called Mounjaro, are not excluded from other forms of treatment.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The National Institute for Health and Care Excellence (NICE) is the independent body responsible for developing authoritative, evidence-based recommendations for the NHS on whether new medicines represent a clinically and cost-effective use of resources. NICE estimated that approximately 3.4 million people are eligible for tirzepatide to treat obesity.
The National Health Service is currently rolling out tirzepatide in primary care, prioritising those with the highest clinical need first. NHS England has worked with clinical experts, integrated care boards, patient and public representatives, healthcare professionals, charities and royal colleges on its prioritisation approach, which it set out in its interim commissioning guidance. This is available at the following link:
As part of the rollout plans, the NHS will look at different service models, including digital and community options and will speed up roll out if possible. Progress on the NHS rollout of tirzepatide will be reviewed by NICE in three years.
For those not currently eligible for tirzepatide, there are a variety of weight management services provided by the NHS and local government. These range from multi-component behavioural programmes to specialist services for those living with severe obesity and associated co-morbidities. All weight management services will have some form of eligibility criteria to ensure that they are targeted at those most likely to benefit. For example, the NHS Digital Weight Management Programme is a behavioural programme primarily aimed at adults living with obesity who also have type 2 diabetes and/or hypertension.
Asked by: Mohammad Yasin (Labour - Bedford)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what guidance his Department has issued to local authorities on offering Individual Service Funds to patients.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
Under the Care Act 2014, everyone whose needs are met by the local authority (LA) must receive a personal budget as part of the care and support plan. The budget sets out how much of the cost of care will be met by the LA and how much will be met by the adult.
Individual Service Funds (ISFs) are one of the ways in which the personal budget can be deployed. It allows for a third-party provider to hold and manage the budget on behalf of the individual.
Guidance on ISFs is set out in the Care and Support Statutory (CASS) Guidance, issued under the Care Act 2014. The CASS guidance sets out that LAs should offer ISFs where possible and provide clear information on how they work. Where an ISF arrangement is not available locally, the LA should explore arrangements to develop this offer and should be receptive to requests to create arrangements with specified providers.
In addition, and supported by the Department, Think Local Act Personal has produced guidance for LAs on ISFs, which can be found on their website, at the following link:
The Care Quality Commission is assessing how well LAs in England are delivering adult social care by looking at how they are performing against their duties under Part 1 of the Care Act 2014. The assessments identify LAs strengths and areas for improvement, facilitating the sharing of good practice and helping us to target support where it is most needed.
The Department has not had discussions with LAs specifically on the effectiveness of the implementation of ISFs under the Care Act 2014.
Asked by: Mohammad Yasin (Labour - Bedford)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what discussions his Department has had with local authorities on the effectiveness of the implementation of Individual Service Funds under the Care Act 2014.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
Under the Care Act 2014, everyone whose needs are met by the local authority (LA) must receive a personal budget as part of the care and support plan. The budget sets out how much of the cost of care will be met by the LA and how much will be met by the adult.
Individual Service Funds (ISFs) are one of the ways in which the personal budget can be deployed. It allows for a third-party provider to hold and manage the budget on behalf of the individual.
Guidance on ISFs is set out in the Care and Support Statutory (CASS) Guidance, issued under the Care Act 2014. The CASS guidance sets out that LAs should offer ISFs where possible and provide clear information on how they work. Where an ISF arrangement is not available locally, the LA should explore arrangements to develop this offer and should be receptive to requests to create arrangements with specified providers.
In addition, and supported by the Department, Think Local Act Personal has produced guidance for LAs on ISFs, which can be found on their website, at the following link:
The Care Quality Commission is assessing how well LAs in England are delivering adult social care by looking at how they are performing against their duties under Part 1 of the Care Act 2014. The assessments identify LAs strengths and areas for improvement, facilitating the sharing of good practice and helping us to target support where it is most needed.
The Department has not had discussions with LAs specifically on the effectiveness of the implementation of ISFs under the Care Act 2014.
Asked by: Mohammad Yasin (Labour - Bedford)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if his Department will take steps to ensure that historic (a) NHS and (b) GP records can be reviewed to identify women who were prescribed Diethylstilbestrol between the 1940s and 1970s.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The issue of diethylstilbesterol (DES) and vaginal carcinoma in the daughters of women who took DES during pregnancy was reviewed by the Committee on Safety of Medicines (CSM) in the early 1970s. In 1973, the CSM wrote to all doctors to inform them of the results of a study into the topic from the United States, and the absence of identified cases in the United Kingdom.
The work of the committee predates the existence of the Medicines and Healthcare products Regulatory Agency (MHRA), when medicines vigilance was only in its infancy and there were no electronic records and no systematic monitoring of prescriptions.
There has been a step change in reporting and record keeping since this time, and today's regulatory frameworks are significantly different, with much stricter post-authorisation monitoring allowing for earlier identification and action on emerging safety issues. The MHRA regulates medicines supplied in the UK. Its activity spans the whole of a medicine’s lifecycle. The MHRA keeps the safety of all medicines under continual review.
Government advice currently is that routine cervical screening is appropriate for those who believe they were exposed to DES in utero. Further information is available at the following link:
Participation in the National Breast Screening Programme is also recommended. Pregnant women who know that they were exposed in utero to DES should inform their obstetrician and be aware of the increased risks of ectopic pregnancy and preterm labour.
The Department does not have any plans to establish a public inquiry into the historic prescribing of DES.
Asked by: Mohammad Yasin (Labour - Bedford)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether his Department plans to establish an independent inquiry into the historic prescribing of Diethylstilbestrol.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The issue of diethylstilbesterol (DES) and vaginal carcinoma in the daughters of women who took DES during pregnancy was reviewed by the Committee on Safety of Medicines (CSM) in the early 1970s. In 1973, the CSM wrote to all doctors to inform them of the results of a study into the topic from the United States, and the absence of identified cases in the United Kingdom.
The work of the committee predates the existence of the Medicines and Healthcare products Regulatory Agency (MHRA), when medicines vigilance was only in its infancy and there were no electronic records and no systematic monitoring of prescriptions.
There has been a step change in reporting and record keeping since this time, and today's regulatory frameworks are significantly different, with much stricter post-authorisation monitoring allowing for earlier identification and action on emerging safety issues. The MHRA regulates medicines supplied in the UK. Its activity spans the whole of a medicine’s lifecycle. The MHRA keeps the safety of all medicines under continual review.
Government advice currently is that routine cervical screening is appropriate for those who believe they were exposed to DES in utero. Further information is available at the following link:
Participation in the National Breast Screening Programme is also recommended. Pregnant women who know that they were exposed in utero to DES should inform their obstetrician and be aware of the increased risks of ectopic pregnancy and preterm labour.
The Department does not have any plans to establish a public inquiry into the historic prescribing of DES.